Key Takeaways
- Shares of Ionis Pharmaceuticals plummeted approximately 20% following unsuccessful Phase 3 CARDIO-TTRansform trial results for eplontersen
- Collaboration partner AstraZeneca experienced an approximate 9% decline following the announcement
- The experimental therapy demonstrated no effectiveness in participants already receiving stabilizer treatment, representing the majority of trial enrollees
- Among patients not using stabilizers, the drug achieved a 29% reduction in risk, providing limited encouragement
- Competing pharmaceutical companies Alnylam and BridgeBio experienced double-digit gains as a major competitor exits the ATTR-CM market
Shares of Ionis Pharmaceuticals (IONS) tumbled between 17-20% during Thursday trading after the biotechnology firm and collaboration partner AstraZeneca (AZN) disclosed that eplontersen did not achieve its primary objective in the Phase 3 CARDIO-TTRansform clinical study.
Ionis Pharmaceuticals, Inc., IONS
The clinical investigation evaluated eplontersen’s ability to lower the incidence of cardiovascular mortality and recurring cardiovascular complications in individuals diagnosed with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) versus placebo treatment across a 140-week period. The results disappointed.
IONS closed Thursday’s session down approximately 17.59%. This decline compounds a year-to-date decrease of 11.78%, although shares remain elevated roughly 99% compared to twelve months earlier.
American depositary receipts of AstraZeneca dropped about 9% following the identical announcement, demonstrating the substantial stakes both organizations held in this clinical outcome.
The study enrolled participants where 57% were already receiving stabilizer medication at enrollment, with an additional 24% initiating such therapy during the trial period. Within this patient cohort, eplontersen failed to demonstrate therapeutic benefit. This represents a significant challenge, given that stabilizer usage has become standard clinical practice.
Positive Signals in Subset Analysis — But Insufficient for Advancement
Some encouraging findings emerged from the data. Among participants not receiving stabilizer drugs, eplontersen demonstrated a 29% decrease in the composite risk of cardiovascular mortality and recurrent complications. The therapeutic candidate also achieved robust, sustained reductions in transthyretin protein concentrations and successfully met multiple secondary objectives.
However, financial analysts remained skeptical about the limited positive findings as viable development pathways. Stifel analyst Paul Matteis observed that “attempting to engage regulatory authorities with these results would appear questionable.” Neither Ionis nor AstraZeneca indicated intentions to pursue regulatory submissions or initiate additional clinical investigations.
Chief Executive Officer Brett Monia expressed disappointment, highlighting the evolving treatment environment where increasing numbers of patients commence stabilizer therapy prior to trial participation. Complete study data will be unveiled at the European Society of Cardiology Congress scheduled for August 2026.
For Ionis particularly, this setback eliminates anticipated profit-sharing arrangements, royalty payments, and prospective milestone compensation associated with eplontersen’s commercial success in cardiovascular indications.
Competitive Landscape Shifts as Market Narrows
Alnylam Pharmaceuticals and BridgeBio both experienced double-digit percentage gains Thursday. With eplontersen’s commercial prospects in ATTR-CM now uncertain, Alnylam’s Amvuttra appears positioned to maintain its standing as the sole RNA-silencing treatment available in this therapeutic area.
Stifel analyst Matteis characterized the development as “a significant positive” for Amvuttra. Pfizer’s Vyndamax, currently dominating the market with sales exceeding $6 billion in the previous year, likewise stands to gain from reduced competition.
Jefferies analyst Michael Leuchten suggested the more significant concern for AstraZeneca transcends lost revenue projections — it represents a credibility challenge. The pharmaceutical giant had approached the data readout with substantial confidence. “AstraZeneca is recognized for possessing exceptionally strong trial design capabilities,” he observed.
Wall Street consensus ratings on IONS entering Thursday indicated Strong Buy, featuring an average price objective of $104.61. These assessments will likely undergo revision.
Trading activity in IONS reached approximately 3 million shares Thursday, substantially exceeding the three-month daily average volume of 1.86 million shares.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
